pharmaceutical

Kodak has struggled in the age of digital photography. Its stock soared after the Trump administration announced plans to give the company a $765 million loan to create a pharmaceutical line.

As the Trump administration decides not to defend the Affordable Care Act's legal protections for people with pre-existing conditions, questions arise about health insurance and genetic information.

It's not just government-sponsored medical research that's dwindled in the last few years in the U.S. Drug firms have curbed their investment, too, especially in early-stage hunts for new drugs.